Angioedema risk of thrombolytics: an integrated assessment using disproportionality analysis of the USFDA adverse event reporting system, case reviews and meta-analysis
This analysis suggests a consistent association increased angioedema risk with thrombolytic-RAAS-i combination therapy. Findings underscore the importance of careful risk assessment and monitoring in patients receiving RAAS-i therapy, especially those on ACEIs.
Authors
- Kannan Sridharan (ORCID: https://orcid.org/0000-0003-3811-6503)
Institutions
- Arabian Gulf University (BH)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-10-11
- DOI
- https://doi.org/10.1080/14740338.2025.2574667
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00